What is Patent Hemostasis?

Transradial catheterization has become a popular worldwide procedure in the treatment of coronary artery diseases. The principal side effects of transradial approach are hematoma, pseudoaneurysm, bleeding, spasm, and Radial Artery Occlusion (RAO). RAO is the most serious complication following transradial catheterization with an incidence between 2% and 18%, as reported in the literature.

Pathophysiology of RAO is thrombosis in the radial artery, which can cause ischemia of the fingers and even led to amputation in some cases. Moreover, it leads to difficulty in a repeat procedure of coronary angiography using the hand now having the occluded artery. Furthermore, RAO may cause hemodialysis fistula and may require revascularization surgery – assuming that is possible.

Previously, there has been no novel and viable alternative to the current hemostasis bands. The problem of Radial Artery Occlusion has not been fully addressed. There has been no new “Standard for Patient Care” - until the invention and development of the VASOBand compression band.

The VASOBand is the only hemostasis device with the Patent Hemostasis indication for use, as cleared by the FDA.

The VASOBand is designed to assist in achieving hemostasis such that the radial artery will not become occluded and that patency of the radial artery (continuous flow of blood through the radial artery) will be maintained during hemostasis and thereafter.